Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.
Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, Tabrizi R, Magro L, Vanhove B, Blancho G, Moreau P, Gaugler B, Chevallier P, Mohty M.
Malard F, et al. Among authors: mohty m.
Blood. 2017 Nov 16;130(20):2186-2195. doi: 10.1182/blood-2017-05-786137. Epub 2017 Sep 1.
Blood. 2017.
PMID: 28864814
Free article.
Clinical Trial.